PT - JOURNAL ARTICLE AU - Liliya Nazlamova AU - Man-Kim Cheung AU - Jelmer Legebeke AU - Jenny Lord AU - Reuben J. Pengelly AU - William Tapper AU - Gabrielle Wheway TI - High-throughput <em>PRPF31</em> variant characterisation pipeline consistent with ACMG/AMP clinical variant interpretation guidelines AID - 10.1101/2020.04.06.20055020 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.06.20055020 4099 - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055020.short 4100 - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055020.full AB - Mutations in PRPF31 are the second most common cause of the degenerative retinal condition autosomal dominant retinitis pigmentosa. Difficulty in characterising missense variants in this gene presents a significant challenge in providing accurate diagnosis for patients to enable targeted testing of other family members, aid family planning, allow pre-implantation diagnosis and inform eligibility for gene therapy trials. With PRPF31 gene therapy in development, there is an urgent need for tools for accurate molecular diagnosis. Here we present a high-throughput high content imaging assay providing quantitative measure of effect of missense variants in PRPF31 which meets the recently published criteria for a baseline standard in vitro test for clinical variant interpretation. This assay utilizes a new and well-characterized PRPF31+/- human retinal cell line generated using CRISPR gene editing, which allows testing of PRPF31 variants which may be causing disease through either haploinsufficiency or dominant negative effects, or a combination of both. The mutant cells have significantly fewer cilia than wild-type cells, allowing rescue of ciliogenesis with benign or mild variants, but do not totally lack cilia, so dominant negative effects can be observed. The results of the assay provide BS3_supporting evidence to the benign classification of two novel uncharacterized PRPF31 variants and suggest that one novel uncharacterized PRPF31 variant may be pathogenic. We hope that this will be a useful tool for clinical characterisation of PRPF31 variants of unknown significance, and can be extended to variant classification in other ciliopathies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Eye Research Centre Small Award SAC019, Wellcome Trust Seed Award in Science 204378/Z/16/Z, UWE Bristol Quality Research funds and University of Southampton Faculty of Medicine Research Management Committee funds.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA sequence data is available via the Sequence Read Archive, accession PRJNA622794 https://www.ncbi.nlm.nih.gov/sra/PRJNA622794